Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

Journal for ImmunoTherapy of Cancer

Volumn 1, Issue , 2013, Pages

  Ohno, Masasuke ^a,b,d   Ohkuri, Takayuki ^a,d   Kosaka, Akemi ^a,d   Tanahashi, Kuniaki ^b   June, Carl H ^c   Natsume, Atsushi ^b   Okada, Hideho ^a,d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor; Glioblastoma; MicroRNA; MiR 17 92

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA INTERFERON; LENTIVIRUS VECTOR; MICRORNA; MICRORNA 17 92; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSDUCTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 84991035101     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-1-21     Document Type: Article

References (49)

1. Okada H, et al: Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009, 29:1-42.
2. Aguilar LK, Arvizu M, Aguilar-Cordova E, Chiocca EA: The spectrum of vaccine therapies for patients with glioblastoma multiforme. Curr Treat Options Oncol 2012, 13:437-450.
3. Ruzevick J, Jackson C, Phallen J, Lim M: Clinical trials with immunotherapy for high-grade glioma. Neurosurg Clin N Am 2012, 23:459-470.
4. Okada H, et al: Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With {alpha}-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol 2011, 29:330-336.
5. Kalos M, et al: T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci Transl Med 2011, 3:95ra73.
6. Porter DL, Levine BL, Kalos M, Bagg A, June CH: Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med 2011, 365:725-733.
7. Brentjens RJ, et al: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
8. Kochenderfer JN, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
9. Facoetti A, et al: Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005, 11:8304-8311.
10. Yeung JT, et al: LOH in the HLA Class I region at 6p21 is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clin Cancer Res 2013. Epub ahead of print.
11. Pule MA, et al: A Chimeric T Cell Antigen Receptor that Augments Cytokine Release and Supports Clonal Expansion of Primary Human T Cells. Mol Ther 2005, 12:933-941.
12. Carpenito C, et al: Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci 2009, 106:3360-3365.
13. Imai C, et al: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
14. Moeller M, et al: A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 2004, 11:371-379.
15. Morgan RA, et al: Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Mol Ther 2010, 18:843-851.
16. Hatanpaa KJ, Burma S, Zhao D, Habib AA: Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12:675-684.
17. Mukasa A, et al: Mutant EGFR is required for maintainenece of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 2010, 107:2616-2621.
18. Heimberger AB, Suki D, Yang D, Shi W, Aldape K: The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 2005, 3:38.
19. Heimberger AB, et al: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005, 11:1462-1466.
20. Zhu X, et al: Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners. Cancer Immunol Immunother 2010, 59:1401-1409.
21. Fujita M, et al: Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells-Significant Roles of CXCL10. Cancer Res 2009, 69:1587-1595.
22. Nishimura F, et al: Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFNinducible protein-10. Cancer Res 2006, 66:4478-4487.
23. Ueda R, et al: Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A 2009, 106:10746-10751.
24. Kohanbash G, Okada H: MicroRNAs and STAT interplay. Semin Cancer Biol 2012, 22:70-75.
25. Xiao C, et al: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008, 9:405-414.
26. Sasaki K, et al: miR-17-92 expression in differentiated T cells-Implications for cancer immunotherapy. J Transl Med 2010, 8:17. URL: http://www.translational-medicine.com/content/8/1/17.
27. Stupp R, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
28. Salaun B, et al: Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. J Transl Med 2011, 9:44.
29. Wu T, et al: Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc Natl Acad Sci U S A 2012, 109:9965-9970.
30. Jiang S, et al: Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 2011, 118:5487-5497.
31. Olive V, Li Q, He L: mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev 2013, 253:158-166.
32. Molitoris JK, McColl KS, Distelhorst CW: Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17 92 contributes to the induction of Bim and initiation of apoptosis. Mol Endocrinol 2011, 25:409-420.
33. van Haaften G, Agami R: Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 2010, 24:1-4.
34. Zhao Y, et al: Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor. Cancer Res 2010, 70:9053-9061.
35. Morgan RA, et al: Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012, 23:1043-1053.
36. Sampson JH, et al: Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. J Clin Oncol 2010, 28:4722-4729.
37. Kahlon KS, et al: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64:9160-9166.
38. Kong S, et al: Suppression of human glioma xenografts with secondgeneration IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012, 18:5949-5960.
39. Ahmed N, et al: HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors. Clin Cancer Res 2010, 16:474-485.
40. Chow KK, et al: T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. Mol Ther 2012, 21:629-637.
41. Schulte A, et al: Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin Cancer Res 2012, 18:1901-1913.
42. Zhang H, et al: 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007, 179:4910-4918.
43. Litterman AJ, et al: Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol 2013, 190:6259-6268.
44. Sanchez-Perez LA, et al: Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One 2013, 8:e59082.
45. Hammond LA, et al: Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999, 17:2604-2613.
46. Sasaki K, et al: Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 2007, 67:6451-6458.
47. Zhu X, et al: Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007, 5:10.
48. Okamoto S, et al: Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Br J Cancer 1996, 73:1366-1372.
49. Nakayashiki N, et al: Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor. Jpn J Cancer Res 2000, 91:1035-1043.